Efficacy of Favipiravir in the Treatment of Moderate COVID-19 Patients: A Randomized, Open-label, Controlled Clinical Trial
Shabnam Tehrani, Davood Yadegarynia, Afshin Bagherzade, Latif Gachkar, Amirreza Keyvanfar
Mediterranean Journal of Infection Microbes and Antimicrobials, doi:10.4274/mjima.galenos.2022.2022.30
Since the beginning of the Coronavirus disease-2019 (COVID-19) pandemic, scientists have studied many drugs to treat it, but none of them have been approved as a complete cure. Favipiravir is one of those drugs that effectively clears the body from the virus by interfering with the process of replication. This study aimed to determine the efficacy of favipiravir compared with supportive medication to treat moderate COVID-19 patients. Materials and Methods: In this randomized, open-label, controlled clinical trial, we examined the efficacy of favipiravir to treat moderate COVID-19 patients. The study was conducted in Labbafinejad Hospital (Tehran, Iran) from April to September 2021. A 1:1 ratio of eligible patients were assigned to the intervention and control groups. The control group received supportive medication. In addition to supportive medication, the intervention group received favipiravir. The primary endpoint was the hospitalization rate during the seven-day follow-up. And the secondary endpoints were symptoms, signs, and laboratory tests of the patients. Results: Out of 78 patients who were included in the study, 40 patients were assigned to the control group and 38 patients were assigned to the intervention group. At the beginning of treatment, the respiratory rate was higher in the intervention group (p=0.001), however, on the fifth (p=0.001) and seventh (p<0.001) days, it was significantly lower in the intervention group. In addition, oxygen saturation at the beginning of treatment was lower in the intervention group (p<0.001); however, on the fifth (p=0.016) and seventh (p<0.001) days, it was significantly higher in the intervention group. Furthermore, the consumption of favipiravir was not associated with the hospitalization rate (p=0.200). Conclusion: Favipiravir enhances respiratory manifestations in patients with moderate COVID-19 when compared to supportive medication alone.
Ethics Ethics Committee Approval: The Ethics Committee of the School of Medicine, of Shahid Beheshti University of Medical Sciences, approved this study on March 3, 2021 (approval ID: IR.SBMU.MSP.REC.1399.750).
Informed Consent: Consent form was filled out by all participants. Peer-review: Externally peer-reviewed. Financial Disclosure: The authors declared that this study received no financial support.
Authorship Contributions
Concept
References
Al-Muhsen, Sharif-Askari, Basamh, Alyounes, Jabaan et al., Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia, Front Med
Alamer, Alrashed, Alfaifi, Alosaimi, Alhassar et al., Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis, Curr Med Res Opin
Chen, Zhang, Huang, Yin, Cheng et al., Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial, Front Pharmacol
Chen, Zhang, Huang, Yin, Cheng et al., Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial, Front Pharmacol
Gandhi, Lynch, Rio, Mild or Moderate Covid-19, N Engl J Med
Han, Ren, Li, Yan, Ma et al., Advances and challenges in the prevention and treatment of COVID-19, Int J Med Sci
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clin Infect Dis
Jean, Lee, Hsueh, Treatment options for COVID-19: The reality and challenges, J Microbiol Immunol Infect
Joshi, Parkar, Ansari, Vora, Talwar et al., Role of favipiravir in the treatment of COVID-19, Int J Infect Dis
Lou, Liu, Yao, Hu, Su et al., Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial, Eur J Pharm Sci
Manabe, Kambayashi, Akatsu, Kudo, Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis, BMC Infect Dis
Marra, Kobayashi, Suzuki, Alsuhaibani, Tofaneto et al., Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and metaanalysis, J Infect
Mckee, Sternberg, Stange, Laufer, Naujokat, Candidate drugs against SARS-CoV-2 and COVID-19, Pharmacol Res
Mortaz, Bassir, Roofchayee, Dezfuli, Jamaati et al., Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra, Int Immunopharmacol
Samudrala, Kumar, Choudhary, Thakur, Wadekar et al., Virology, pathogenesis, diagnosis and in-line treatment of COVID-19, Eur J Pharmacol
Shinkai, Tsushima, Tanaka, Hagiwara, Tarumoto et al., Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial, Infect Dis Ther
Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis, Virol J
Solaymani-Dodaran, Ghanei, Bagheri, Qazvini, Vahedi et al., Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia, Int Immunopharmacol
Szabo, Lenart, Petrik, Gaspar, Kiss-Dala et al., Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary, Geroscience
Tehrani, Khabiri, Moradi, Mosavat, Khabiri, Evaluation of vitamin D levels in COVID-19 patients referred to Labafinejad hospital in Tehran and its relationship with disease severity and mortality, Clin Nutr ESPEN
Tu, Chien, Yarmishyn, Lin, Luo et al., A Review of SARS-CoV-2 and the Ongoing Clinical Trials, Int J Mol Sci
Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int J Infect Dis
Wang, Li, Liu, An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics, J Infect Public Health
Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, Jama
Zhao, Zhang, Zhu, Chen, Chen et al., Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, openlabel, randomized trial, Int Immunopharmacol
{ 'indexed': {'date-parts': [[2022, 8, 10]], 'date-time': '2022-08-10T11:11:51Z', 'timestamp': 1660129911967},
'reference-count': 0,
'publisher': 'Galenos Yayinevi',
'issue': '1',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'DOI': '10.4274/mjima.galenos.2022.2022.30',
'type': 'journal-article',
'created': {'date-parts': [[2022, 6, 28]], 'date-time': '2022-06-28T12:48:26Z', 'timestamp': 1656420506000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Efficacy of Favipiravir in the Treatment of Moderate COVID-19 Patients: A Randomized, '
'Open-label, Controlled Clinical Trial',
'prefix': '10.4274',
'volume': '11',
'author': [ {'given': 'Shabnam', 'family': 'TEHRANI', 'sequence': 'first', 'affiliation': []},
{'given': 'Davood', 'family': 'YADEGARYNIA', 'sequence': 'additional', 'affiliation': []},
{'given': 'Afshin', 'family': 'BAGHERZADE', 'sequence': 'additional', 'affiliation': []},
{'given': 'Latif', 'family': 'GACHKAR', 'sequence': 'additional', 'affiliation': []},
{'given': 'Amirreza', 'family': 'KEYVANFAR', 'sequence': 'additional', 'affiliation': []}],
'member': '2811',
'published-online': {'date-parts': [[2022, 8, 10]]},
'container-title': 'Mediterranean Journal of Infection Microbes and Antimicrobials',
'original-title': [],
'deposited': { 'date-parts': [[2022, 8, 10]],
'date-time': '2022-08-10T10:54:33Z',
'timestamp': 1660128873000},
'score': 1,
'resource': {'primary': {'URL': 'https://mjima.org/pdf.php?&id=340'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 8, 10]]},
'references-count': 0,
'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2022, 8, 10]]}},
'URL': 'http://dx.doi.org/10.4274/mjima.galenos.2022.2022.30',
'relation': {},
'ISSN': ['2147-673X'],
'subject': ['Infectious Diseases', 'Microbiology (medical)', 'General Immunology and Microbiology'],
'container-title-short': 'mjima',
'published': {'date-parts': [[2022, 8, 10]]}}
